Ratings NEUCA S.A.

Equities

NEU

PLTRFRM00018

Market Closed - Warsaw S.E. Other stock markets 09:25:55 26/04/2024 pm IST			5-day change	1st Jan Change
904 ^PLN	+1.01%		+0.56%	-2.27%

23/03	NEUCA S.A. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
2023	NEUCA S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	CI

Summary

The company presents an interesting fundamental situation from a short-term investment perspective.

Strengths

The company is one of the most undervalued, with an "enterprise value to sales" ratio at 0.33 for the 2024 fiscal year.
Analysts covering this company mostly recommend stock overweighting or purchase.
Consensus analysts have strongly revised their opinion of the company over the past 12 months.

Weaknesses

As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
Low profitability weakens the company.
The average consensus view of analysts covering the stock has deteriorated over the past four months.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Pharmaceuticals

	1st Jan change	Capi.	ESG Refinitiv
NEUCA S.A.	-2.27%	998M	B-
MCKESSON CORPORATION	+17.35%	71.39B	C+
SINOPHARM GROUP CO. LTD.	+5.38%	8.59B	C
SHANGHAI PHARMACEUTICALS HOLDING CO., LTD	+6.69%	8.19B	B
HUADONG MEDICINE CO., LTD	-20.96%	7.91B	B-
H. LUNDBECK A/S	+0.49%	4.54B	B-
JOINTOWN PHARMACEUTICAL GROUP CO., LTD	+17.12%	4.31B	B+
EBOS GROUP LIMITED	-3.38%	3.93B	B-
GALENICA AG	-2.61%	3.86B	B
CHINA NATIONAL MEDICINES CORPORATION LTD.	+22.08%	3.64B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes